XML 12 R2.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Pay vs Performance Disclosure [Table]

Pay versus Performance

The following table discloses additional compensation information of our CEO and other NEOs (Other NEOs), including “compensation actually paid” during the specified years alongside total shareholder return (TSR) and net income metrics:


											Value of initial fixed $100 investment based on:
	Summary compensation table total for CEO		Compensation actually paid to CEO(2)(3)			Average summary compensation table total for Other NEOs		Average Compensation actually paid to Other NEOs(2)(4)			Total shareholder return(5)		Peer group total shareholder return(5)		Net income(6)
Year(1)	($)		($)			($)		($)			($)		($)		($ millions)
2022		9,048,432		(2,065,105	)		4,191,618		(2,394,074	)		204.75		87.61		(267	)
2021		9,483,339		14,577,932			5,939,512		7,091,681			400.69		117.83		53
2020		5,685,664		12,015,409			5,363,707		10,455,559			257.03		148.03		(123	)

(1) Our CEO for each of the years presented was Dr. Rosen. Our Other NEOs for 2022 were Bob Goeltz, Juan Jaen, Jennifer Jarret and Dimitry Nuyten. Our Other NEOs for 2021 were Bob Goeltz, Juan Jaen, Jennifer Jarret, Carolyn Tang and William Grossman. Our Other NEOs for 2020 were Jennifer Jarrett and William Grossman.

(2) Fair value or change in fair value, as applicable, of equity awards in the "compensation actually paid" columns was determined by reference to (i) for RSU awards, closing price on applicable year-end dates or, in the case of vesting dates, the actual vesting price and (ii) for stock options, the fair value estimated using a binomial lattice model as of the applicable year-end or vesting date(s). Key inputs included the contractual terms of each agreement such as vesting date, maturity date, and exercise price, while additional key inputs included the closing stock price, volatility, dividend rates, risk free rates, and an early-exercise factor which were all determined as of the revaluation date.

(3) The adjustments made to the summary compensation table total for Dr. Rosen's for each year presented above to determine compensation actually paid to Dr. Rosen in such year are shown in the tables below:


	2022			2021			2020
Summary compensation table total		9,048,432			9,483,339			5,685,664
Less, value of stock & option awards		(8,292,320	)		(8,548,858	)		(5,356,475	)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding		3,788,462			7,142,260			7,893,097
Plus change in fair value of prior year awards that are outstanding and unvested		(5,490,389	)		3,923,736			1,828,423
Plus FMV as of the vesting date of awards granted this year and that vested this year		1,608,814			1,783,385			1,108,163
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year		(2,728,104	)		794,070			856,538
Total adjustments		(11,113,537	)		5,094,593			6,329,745
Compensation actually paid		(2,065,105	)		14,577,932			12,015,409

(4) The adjustments made to the average summary compensation table total for Other NEOs for each year presented above to determine average compensation actually paid to Other-NEOs in such year are shown in the tables below:


	2022			2021			2020
Summary compensation table total		4,191,618			5,939,512			5,363,707
Less, value of stock & option awards		(3,444,851	)		(5,298,516	)		(4,864,788	)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding		1,848,729			3,797,282			6,969,591
Plus change in fair value of prior year awards that are outstanding and unvested		(4,050,986	)		2,678,504			1,656,950
Plus FMV as of the vesting date of awards granted this year and that vested this year		528,662			1,094,353			509,856
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year		(1,467,247	)		678,367			820,243
Less, prior year fair value of prior year awards that failed to vest this year		-			(1,827,217	)		-
Plus adjustments for stock modification		-			29,396			-
Total adjustments		(6,585,693	)		1,152,169			5,091,852
Compensation actually paid		(2,394,074	)		7,091,681			10,455,559

(5) TSR figures assume an initial investment in our common stock of $100 on December 31, 2019. The peer group referenced for purpose of the TSR comparison is the group of companies included in the S&P Biotechnology Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 27.

(6) Reflects after-tax net income attributable to stockholders prepared in accordance with GAAP for each of the years shown.

Named Executive Officers, Footnote [Text Block]

Our CEO for each of the years presented was Dr. Rosen. Our Other NEOs for 2022 were Bob Goeltz, Juan Jaen, Jennifer Jarret and Dimitry Nuyten. Our Other NEOs for 2021 were Bob Goeltz, Juan Jaen, Jennifer Jarret, Carolyn Tang and William Grossman. Our Other NEOs for 2020 were Jennifer Jarrett and William Grossman.

Peer Group Issuers, Footnote [Text Block]

The peer group referenced for purpose of the TSR comparison is the group of companies included in the S&P Biotechnology Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 27.

PEO Total Compensation Amount

$ 9,048,432

$ 9,483,339

$ 5,685,664

PEO Actually Paid Compensation Amount

$ (2,065,105)

14,577,932

12,015,409

Adjustment To PEO Compensation, Footnote [Text Block]

Fair value or change in fair value, as applicable, of equity awards in the "compensation actually paid" columns was determined by reference to (i) for RSU awards, closing price on applicable year-end dates or, in the case of vesting dates, the actual vesting price and (ii) for stock options, the fair value estimated using a binomial lattice model as of the applicable year-end or vesting date(s). Key inputs included the contractual terms of each agreement such as vesting date, maturity date, and exercise price, while additional key inputs included the closing stock price, volatility, dividend rates, risk free rates, and an early-exercise factor which were all determined as of the revaluation date.The adjustments made to the summary compensation table total for Dr. Rosen's for each year presented above to determine compensation actually paid to Dr. Rosen in such year are shown in the tables below:


	2022			2021			2020
Summary compensation table total		9,048,432			9,483,339			5,685,664
Less, value of stock & option awards		(8,292,320	)		(8,548,858	)		(5,356,475	)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding		3,788,462			7,142,260			7,893,097
Plus change in fair value of prior year awards that are outstanding and unvested		(5,490,389	)		3,923,736			1,828,423
Plus FMV as of the vesting date of awards granted this year and that vested this year		1,608,814			1,783,385			1,108,163
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year		(2,728,104	)		794,070			856,538
Total adjustments		(11,113,537	)		5,094,593			6,329,745
Compensation actually paid		(2,065,105	)		14,577,932			12,015,409

Non-PEO NEO Average Total Compensation Amount

$ 4,191,618

5,939,512

5,363,707

Non-PEO NEO Average Compensation Actually Paid Amount

$ (2,394,074)

7,091,681

10,455,559

Adjustment to Non-PEO NEO Compensation Footnote [Text Block]

The adjustments made to the average summary compensation table total for Other NEOs for each year presented above to determine average compensation actually paid to Other-NEOs in such year are shown in the tables below:


	2022			2021			2020
Summary compensation table total		4,191,618			5,939,512			5,363,707
Less, value of stock & option awards		(3,444,851	)		(5,298,516	)		(4,864,788	)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding		1,848,729			3,797,282			6,969,591
Plus change in fair value of prior year awards that are outstanding and unvested		(4,050,986	)		2,678,504			1,656,950
Plus FMV as of the vesting date of awards granted this year and that vested this year		528,662			1,094,353			509,856
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year		(1,467,247	)		678,367			820,243
Less, prior year fair value of prior year awards that failed to vest this year		-			(1,827,217	)		-
Plus adjustments for stock modification		-			29,396			-
Total adjustments		(6,585,693	)		1,152,169			5,091,852
Compensation actually paid		(2,394,074	)		7,091,681			10,455,559

Compensation Actually Paid vs. Total Shareholder Return [Text Block]

The graphs below show the relationship between (i) the compensation actually paid to both our CEO and Other NEOs for the years set forth in the Pay versus Performance Table and (ii) the net income/loss and total shareholder return for the corresponding years:

Compensation Actually Paid vs. Net Income [Text Block]

Total Shareholder Return Vs Peer Group [Text Block]

TSR figures assume an initial investment in our common stock of $100 on December 31, 2019.

Total Shareholder Return Amount

$ 204.75

400.69

257.03

Peer Group Total Shareholder Return Amount

87.61

117.83

148.03

Net Income (Loss)

$ (267,000,000)

$ 53,000,000

$ (123,000,000)

PEO Name

Dr. Rosen

Additional 402(v) Disclosure [Text Block]

As described above under “Compensation Discussion and Analysis,” our executive compensation program is built around a pay-for-performance framework. While we utilize various performance measures to align executive compensation with company performance, these measures are focused on the clinical development of our investigational products and, as such, are non-financial in nature. Moreover, we generally seek to incentivize long-term performance, and therefore do not specifically align the company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. As a result, we do not have a financial performance measure as described in Item 402(v)(2)(vi) of Regulation S-K to link compensation actually paid to our performance.

Non PEO Name

Bob Goeltz, Juan Jaen, Jennifer Jarret and Dimitry Nuyten

Bob Goeltz, Juan Jaen, Jennifer Jarret, Carolyn Tang and William Grossman

Jennifer Jarrett and William Grossman

PEO [Member]

Pay vs Performance Disclosure [Table]

Adjustment to Compensation Amount

$ (11,113,537)

$ 5,094,593

$ 6,329,745

PEO [Member] | Less, Value of Stock & Options Awards

Pay vs Performance Disclosure [Table]